Hengmiao Cheng

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

Jing Yuan, Pramod P. Mehta, Min-Jean Yin et al. · Molecular Cancer Therapeutics · 2011 · 159 citations · Full text

Antitumor Activity, Pten Loss, Cancer Biology +22

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 <i>H</i> -[1,2,3]triazolo[4,5- <i>b</i> ]pyrazin-6-yl)-1 <i>H</i> -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer

J. Jean Cui, Michele McTigue, Mitchell D. Nambu et al. · Journal of Medicinal Chemistry · 2012 · 103 citations · Full text

Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Simon Planken, Douglas C. Behenna, Sajiv K. Nair et al. · Journal of Medicinal Chemistry · 2017 · 89 citations · Full text

Molecular Biology, Wild-type Egfr, Chemical Biology +21

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

Hengmiao Cheng, Chunze Li, Simon Bailey et al. · ACS Medicinal Chemistry Letters · 2012 · 78 citations · Full text

Drug Target, Pharmaceutical Chemistry, Empirical Scaling Tool +18

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

Hengmiao Cheng, Shubha Bagrodia, Simon Bailey et al. · MedChemComm · 2010 · 73 citations · Full text

Drug Target, Tumor Biology, Drug Design +16